HDLForum

register login
  • Skip to content
  • Homesummary
  • About HDL Forum 
  • News 
    • News
    • Meeting reports
    • Forthcoming Meetings
  • Resources 
    • Slides
    • Societies
    • Guidelines
    • Links
    • Glossary
  • Ask the Expert 
    • Viewpoints
    • Roundtable discussion
    • Expert Opinion
  • HDL Essentials 
    • About CETPi Forum
    • About HDL Forum
  • Register 
  • Contact 

Slide Resources

HDL and Atherosclerosis

  • HDL and Atherosclerosis: an overview
  • HDL cholesterol and cardiovascular risk
  • Raising HDL cholesterol: therapeutic considerations

Key trials

  • Evacetrapib
  • Dal-PLAQUE
  • Dal-VESSEL
  • Dalcetrapib: 48-week trial
  • DEFINE
  • ILLUMINATE

  • ACCORD
  • VA-HIT

  • HPS2-THRIVE
  • AIM-HIGH
  • Oxford nicotinic acid trial
  • ARBITER 6-HALTS
  • ARBITER 2 and 3 trials
  • HATS: HDL Atherosclerosis Treatment Study
  • Coronary Drug Project
  • FATS: Familial Atherosclerosis Treatment Study
  • CLAS
  • COMPELL
  • SEACOAST
  • Niacin-laropiprant

Editors

  • Professor Kerry-Anne Rye

    Head of Lipid Research Group
    Read more...


  • Professor Philip Barter

    Director
    Read more...


  • Professor John Chapman

    Director
    Read more...

     


    Click here for the Editorial Board

REGISTRATION IS FREE TO ALL HEALTHCARE PROFESSIONALS

 Supported by unrestricted medical
educational grants from

 

 Supporters have no editorial influence
over the content of this website

Unless otherwise indicated, opinions expressed in HDL Forum are those of the contributors.  Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the sponsor, publisher, editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2012 . All rights reserved.



  • Forgot your password?
  • Forgot your username?
  • Create an account